TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07234162: A Phase 3, Open-Label, Randomized, Multinational Study to Investigate the Anti-tumor Efficacy of Golidocitinib Versus Investigator's Choice in Adult Patients With Relapsed/Refractory Peripheral T-cell Lymphoma

Sponsor: Dizal Pharmaceuticals · Phase: PHASE3 · Area: ONCOLOGY · Target Enrollment: 218 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$787,248

Rescue Site Savings

+$524,832

Unlock Full NCT07234162 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07234162 Rescue Dossier →